OverviewSuggest Edit

CRISPR Therapeutics is a gene editing company focused on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform.

TypePublic
Founded2013
HQZug, CH
Websitecrisprtx.com
Employee Ratings3.6

Latest Updates

Employees (est.) (May 2021)410(+35%)
Job Openings37
Revenue (FY, 2020)$719 K(-99%)
Share Price (Jun 2021)$113.3(+4%)
Cybersecurity ratingBMore

Key People/Management at CRISPR Therapeutics

Samarth Kulkarni

Samarth Kulkarni

Chief Executive Officer & Director
Steve Caffé

Steve Caffé

Head of Regulatory Affairs
Shaun Foy

Shaun Foy

Co-Founder
Tony Ho

Tony Ho

Head of Research and Development
Stephen Kennedy

Stephen Kennedy

Head of Technical Operations
James Kasinger

James Kasinger

General Counsel and Secretary to the Board of Directors
Show more

CRISPR Therapeutics Office Locations

CRISPR Therapeutics has offices in Zug, Cambridge, San Francisco and Greater London
Zug, CH (HQ)
Baarerstrasse 14/V8
Greater London, GB
85 Tottenham Court Rd
Cambridge, MA, US
610 Main St
San Francisco, CA, US
455 Mission Bay Boulevard South, San Francisco
Show all (4)

CRISPR Therapeutics Financials and Metrics

CRISPR Therapeutics Revenue

CRISPR Therapeutics's revenue was reported to be $719 k in FY, 2020
USD

Revenue (FY, 2020)

719.0k

Net income (FY, 2020)

(348.9m)

EBIT (FY, 2020)

(354.4m)

Market capitalization (4-Jun-2021)

8.6b

Closing stock price (4-Jun-2021)

113.3

Cash (31-Dec-2020)

1.2b

EV

7.5b
CRISPR Therapeutics's current market capitalization is $8.6 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

5.2m41.0m3.1m289.6m719.0k

General and administrative expense

31.1m35.8m48.3m63.5m88.2m

R&D expense

42.2m69.8m113.8m179.4m266.9m

Operating expense total

73.3m105.6m162.1m242.9m355.2m
Quarterly
USDQ3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

1.5m2.7m3.6m2.4m1.4m1.1m563.0k328.0k318.0k211.9m157.0k44.0k148.0k

General and administrative expense

4.1m8.6m7.8m8.1m8.8m12.7m10.2m14.9m15.8m15.5m19.6m21.4m21.5m

R&D expense

12.1m14.8m17.1m17.8m19.5m25.6m39.8m33.8m39.5m57.2m54.2m59.4m71.0m

Operating expense total

16.2m23.4m24.9m26.0m28.4m38.4m50.0m48.8m55.3m72.8m73.7m80.7m92.5m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

315.5m239.8m456.6m943.8m1.2b

Accounts Receivable

3.2m2.6m88.0k99.0k144.0k

Prepaid Expenses

1.5m6.0m9.7m43.7m26.1m

Current Assets

320.2m248.4m466.4m987.5m1.7b
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(23.2m)(68.4m)(165.0m)66.9m(348.9m)

Depreciation and Amortization

925.0k3.0m3.5m4.7m9.2m

Accounts Payable

3.9m(831.0k)12.1m5.0m25.7m

Cash From Operating Activities

(55.3m)(70.1m)(96.2m)56.7m(238.4m)
USDQ3, 2016

Financial Leverage

-4.5 x
Show all financial metrics

CRISPR Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

CRISPR Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

CRISPR Therapeutics Online and Social Media Presence

Embed Graph

CRISPR Therapeutics News and Updates

Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress

CAMBRIDGE, Mass. and ZUG, Switzerland and BOSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced two abstracts detailing updated data from the ongoing CTX001 clinical trials have been accepted for presentat…

CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer

-Collaboration brings together breakthrough gene editing technology and leading natural killer (NK) cell and T cell discovery, development, and manufacturing capabilities-

CRISPR Therapeutics Announces Trials in Progress Poster Presentation at the 2021 American Society of Clinical Oncology Annual Meeting

ZUG, Switzerland and CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a Trials in Progress poster presentation at t…

Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia

BOSTON and CAMBRIDGE, Mass. and ZUG, Switzerland, April 26, 2021 (GLOBE NEWSWIRE) --  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an inves…

Thinking about trading options or stock in Crispr Therapeutics, Caesars Entertainment, GrowGeneration, Apple, or Walt Disney?

NEW YORK, April 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRSP, CZR, GRWG, AAPL, and DIS. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia

- Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001-
Show more

CRISPR Therapeutics Blogs

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results Ray.Beron@west.com Tue, 04/27/2021 - 16:02 CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results April 27, 2021 at 4:01 PM EDT …

CRISPR Therapeutics to Participate in the 20th Annual Needham Virtual Healthcare Conference

CRISPR Therapeutics to Participate in the 20th Annual Needham Virtual Healthcare Conference Reynally.Merca… Tue, 04/06/2021 - 08:01 CRISPR Therapeutics to Participate in the 20th Annual Needham Virtual Healthcare Conference April 6, 2021 at 8:00 AM EDT This re…

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results Ray.Beron@west.com Tue, 02/16/2021 - 16:02 CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results February 16, 2…

CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

ZUG, Switzerland and CAMBRIDGE, Mass. , Nov. 24, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to

CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference

CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference william.meady@… Thu, 09/03/2020 - 08:02 CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference September 3, 2020 at 8:00 AM EDT This release is a…

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results

-Dosing re-initiated in clinical trials of CTX001™ for patients with severe hemoglobinopathies- - CTX001 has received orphan drug designation from the U.S. FDA for sickle cell disease (SCD)- -Expands regenerative medicine portfolio through a collaboration with University Health Network (UHN),
Show more

CRISPR Therapeutics Frequently Asked Questions

  • When was CRISPR Therapeutics founded?

    CRISPR Therapeutics was founded in 2013.

  • Who are CRISPR Therapeutics key executives?

    CRISPR Therapeutics's key executives are Samarth Kulkarni, Steve Caffé and Shaun Foy.

  • How many employees does CRISPR Therapeutics have?

    CRISPR Therapeutics has 410 employees.

  • What is CRISPR Therapeutics revenue?

    Latest CRISPR Therapeutics annual revenue is $719 k.

  • What is CRISPR Therapeutics revenue per employee?

    Latest CRISPR Therapeutics revenue per employee is $1.8 k.

  • Who are CRISPR Therapeutics competitors?

    Competitors of CRISPR Therapeutics include Arrow Pharmaceuticals, AnGes and Omega Therapeutics.

  • Where is CRISPR Therapeutics headquarters?

    CRISPR Therapeutics headquarters is located at Baarerstrasse 14/V8, Zug.

  • Where are CRISPR Therapeutics offices?

    CRISPR Therapeutics has offices in Zug, Cambridge, San Francisco and Greater London.

  • How many offices does CRISPR Therapeutics have?

    CRISPR Therapeutics has 4 offices.